Pharmacologic regimens for knee osteoarthritis prevention: Can they be cost-effective?

Osteoarthritis and Cartilage

Volumn 22, Issue 3, 2014, Pages 415-430

  Losina, E ^a,b,c   Burbine, S A ^a   Suter, L G ^d   Hunter, D J ^e   Solomon, D H ^a,b   Daigle, M E ^a   Dervan, E E ^a   Jordan, J M ^f   Katz, J N ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Disease modifying osteoarthritis drugs; Knee osteoarthritis; Prophylaxis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE QUALITY; HUMAN; KNEE INJURY; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; PROPHYLAXIS; SIMULATION; VERY ELDERLY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; KNEE INJURIES; OSTEOARTHRITIS, KNEE; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; KNEE INJURIES; MALE; MIDDLE AGED; OBESITY; OSTEOARTHRITIS, KNEE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896701908     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.01.005     Document Type: Article

References (80)

1. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
2. Losina E., Niu N.N., Holt H.L., Reichmann W.M., Hunter D.J., Suter L.G., et al. Cost-effectiveness of ACR guideline-based care and lifetime direct medical costs attributable to knee OA management in the US. American College of Rheumatology (ACR) Annual Scientific Meeting 2009, 60 (S10):1177. Arthritis Rheum, Philadelphia, PA.
3. Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009, 15:S230-S235.
4. Woolf A.D., Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003, 81:646-656.
5. Zhang Y., Jordan J.M. Epidemiology of osteoarthritis. Clin Geriatr Med 2010, 26:355-369.
6. Blagojevic M., Jinks C., Jeffery A., Jordan K.P. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 2010, 18:24-33.
7. Hunter D.J. Lower extremity osteoarthritis management needs a paradigm shift. Br J Sports Med 2011, 45:283-288.
8. Hunter D.J., Hellio Le Graverand-Gastineau M.P. How close are we to having structure-modifying drugs available?. Med Clin North Am 2009, 93:223-234. xiii.
9. Losina E., Daigle M.E., Suter L.G., Hunter D.J., Solomon D.H., Walensky R.P., et al. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?. Osteoarthritis Cartilage 2013, 21:655-667.
10. Niu J., Zhang Y.Q., Torner J., Nevitt M., Lewis C.E., Aliabadi P., et al. Is obesity a risk factor for progressive radiographic knee osteoarthritis?. Arthritis Rheum 2009, 61:329-335.
11. Cooper C., Snow S., McAlindon T.E., Kellingray S., Stuart B., Coggon D., et al. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum 2000, 43:995-1000.
12. Wilder F.V., Hall B.J., Barrett J.P., Lemrow N.B. History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment. The Clearwater Osteoarthritis Study. Osteoarthritis Cartilage 2002, 10:611-616.
13. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1253-1258.
14. Holt H.L., Katz J.N., Reichmann W.M., Gerlovin H., Wright E.A., Hunter D.J., et al. Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults. Osteoarthritis Cartilage 2011, 19:44-50.
15. Losina E., Walensky R.P., Reichmann W.M., Holt H.L., Gerlovin H., Solomon D.H., et al. Impact of obesity and knee osteoarthritis on Morbidity and mortality in older Americans. Ann Intern Med 2011, 154:217-226.
16. Centers for Disease Control and Prevention National Center for Health Statistics 2007, National Health Interview Survey (NHIS).
17. Centers for Disease Control and Prevention (CDC) 2005-2006 National Health and Nutrition Examination Survey (NHANES) Data 2006, National Center for Health Statistics (NCHS), U.S. Department of Health and Human Services, Hyattsville, MD.
18. Centers for Disease Control and Prevention (CDC) 2007-2008 National Health and Nutrition Examination Survey (NHANES) Data 2008, National Center for Health Statistics (NCHS), U.S. Department of Health and Human Services, Hyattsville, MD.
19. Arias E. United States life tables, 2006. National Vital Statistics Reports 2010, vol. 58. National Center for Health Statistics, Hyattsville, Maryland 20782-2003, USA.
20. Brazier J., Usherwood T., Harper R., Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. JClin Epidemiol 1998, 51:1115-1128.
21. Diehr P., Patrick D.L., Spertus J., Kiefe C.I., McDonell M., Fihn S.D. Transforming self-rated health and the SF-36 scales to includedeath and improve interpretability. Med Care 2001, 39:670-680.
22. Losina E., Walensky R.P., Kessler C.L., Emrani P.S., Reichmann W.M., Wright E.A., et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med 2009, 169:1113-1121. discussion 1121-1112.
23. Suter L.G., Paltiel A.D., Rome B.N., Solomon D.H., Thornhill T.S., Abrams S.K., et al. Placing a price on medical device innovation: the example of total knee arthroplasty. PLoS One 2013, 8:e62709.
24. Annual Estimates of the Hispanic, White, and Black Resident Populations by Sex and Age for the United States: April 1, 2000 to July 1, 2009 (NC-EST2009-04-HISP/WANH/BA) June 2010, US Census Bureau, Population Division.
25. Pope G.C., Kautter J., Ellis R.P., Ash A.S., Ayanian J.Z., Lezzoni L.I., et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004, 25:119-141.
26. Red Book: Pharmacy's Fundamental Reference: 2010 Edition 2010, PDR Network, LLC, Montvale, NJ.
27. Medicare Current Beneficiary Survey 2006, Centers for Medicare & Medicaid Services.
28. Losina E., Weinstein A.M., Reichmann W.M., Burbine S.A., Solomon D.H., Daigle M.E., et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken) 2013, 65:703-711.
29. Centers for Disease Control and Prevention (CDC) 2003-2004 National Health and Nutrition Examination Survey (NHANES) Data 2004, National Center for Health Statistics (NCHS), U.S. Department of Health and Human Services, Hyattsville, MD.
30. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2001, 15:609-626.
31. Jones A., Doherty M. Intra-articular therapies in osteoarthritis. Osteoarthritis 1998, Oxford University Press, Oxford. K. Brandt, M. Doherty, L. Lohmander (Eds.).
32. Seror P., Pluvinage P., d'Andre F.L., Benamou P., Attuil G. Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in France). Rheumatology (Oxford) 1999, 38:1272-1274.
33. Siegel J.E., Weinstein M.C., Russell L.B., Gold M.R. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1339-1341.
34. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
35. American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-1915.
36. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
37. Richmond J., Hunter D., Irrgang J., Jones M.H., Snyder-Mackler L., Van Durme D., et al. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. JBone Joint Surg Am 2010, 92:990-993.
38. Treatment of Osteoarthritis of the Knee (Non-arthroplasty): Full Guideline 2008, American Academy of Orthopaedic Surgeons, Rosemont, IL. 1st edn.
39. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
40. Medicare Fee Schedules 2010, Centers for Medicare & Medicaid Services.
41. Medicare Hospital Inpatient Prospective Payment System 2011, Centers for Medicare & Medicaid Services.
42. Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) 2009, Agency for Healthcare Research and Quality, Rockville, MD, (accessed December 20, 2013). http://hcupnet.ahrq.gov.
43. Scott D.L., Berry H., Capell H., Coppock J., Daymond T., Doyle D.V., et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology 2000, 39:1095-1101.
44. Katz J.N., Mahomed N.N., Baron J.A., Barrett J.A., Fossel A.H., Creel A.H., et al. Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum 2007, 56:568-574.
45. Paxton E.W., Namba R.S., Maletis G.B., Khatod M., Yue E.J., Davies M., et al. Aprospective study of 80,000 total joint and 5000 anterior cruciate ligament reconstruction procedures in a community-based registry in the United States. JBone Joint Surg Am 2010, 92(Suppl 2):117-132.
46. Bensen W.G., Fiechtner J.J., McMillen J.I., Zhao W.W., Yu S.S., Woods E.M., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999, 74:1095-1105.
47. Goldstein J.L. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. JRheumatol Suppl 2000, 60:25-28.
48. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. NEngl J Med 2005, 352:1071-1080.
49. Briggs A.H., Weinstein M.C., Fenwick E.A., Karnon J., Sculpher M.J., Paltiel A.D. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 2012, 15:835-842.
50. Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) 2008, Agency for Healthcare Research and Quality, Rockville, MD, (accessed December 20, 2013). http://hcupnet.ahrq.gov/.
51. Kamath C.C., Kremers H.M., Vanness D.J., O'Fallon W.M., Cabanela R.L., Gabriel S.E. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003, 6:144-157.
52. Using Ace Inhibitors to Treat High Blood Pressure and Heart Disease: Comparing Effectiveness, Safety, and Price 2011, Consumer Reports Health Best Buy Drugs: Consumers Union of United States, Inc.
53. Using Beta-blockers to Treat High Blood Pressure and Heart Disease: Comparing Effectiveness, Safety, and Price 2011, Consumer Reports Health Best Buy Drugs: Consumers Union of United States, Inc.
54. Evaluating Statin Drugs to Treat High Cholesterol and Heart Disease: Comparing Effectiveness, Safety, and Price 2010, Consumer Reports Health Best Buy Drugs: Consumers Union of United States, Inc.
55. Medicare Hospital Outpatient Prospective Payment System 2010, Centers for Medicare & Medicaid Services.
56. Braithwaite R.S., Meltzer D.O., King J.T., Leslie D., Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 2008, 46:349-356.
57. Ubel P.A., Hirth R.A., Chernew M.E., Fendrick A.M. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 2003, 163:1637-1641.
58. Hidden Costs, Value Lost: Uninsurance in America 2003, Institute of Medicine of the National Academies.
59. Noe L.L., Becker R.V., Gradishar W.J., Gore M., Trotter J.P. The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care 1999, 5:S389-S406.
60. Sanders G.D., Hlatky M.A., Every N.R., McDonald K.M., Heidenreich P.A., Parsons L.S., et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001, 135:870-883.
61. Kessler M.A., Behrend H., Henz S., Stutz G., Rukavina A., Kuster M.S. Function, osteoarthritis and activity after ACL-rupture: 11 years follow-up results of conservative versus reconstructive treatment. Knee Surg Sports Traumatol Arthrosc 2008, 16:442-448.
62. Louboutin H., Debarge R., Richou J., Selmi T.A., Donell S.T., Neyret P., et al. Osteoarthritis in patients with anterior cruciateligament rupture: a review of risk factors. Knee 2009, 16:239-244.
63. Palmieri-Smith R.M., Thomas A.C. Aneuromuscular mechanism of posttraumatic osteoarthritis associated with ACL injury. Exerc Sport Sci Rev 2009, 37:147-153.
64. Messier S.P. Obesity and osteoarthritis: disease genesis and nonpharmacologic weight management. Rheum Dis Clin North Am 2008, 34:713-729.
65. Messier S.P., Mihalko S.L., Legault C., Miller G.D., Nicklas B.J., DeVita P., et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013, 310:1263-1273.
66. Felson D.T., Zhang Y., Anthony J.M., Naimark A., Anderson J.J. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992, 116:535-539.
67. Felson D.T., Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998, 41:1343-1355.
68. Messier S.P., Loeser R.F., Miller G.D., Morgan T.M., Rejeski W.J., Sevick M.A., et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the arthritis, diet, and activity promotion trial. Arthritis Rheum 2004, 50:1501-1510.
69. Muthuri S.G., Hui M., Doherty M., Zhang W. What if we prevent obesity? Risk reduction in knee osteoarthritis estimated through a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 2011, 63:982-990.
70. Mikesky A.E., Mazzuca S.A., Brandt K.D., Perkins S.M., Damush T., Lane K.A. Effects of strength training on the incidence and progression of knee osteoarthritis. Arthritis Rheum 2006, 55:690-699.
71. Riddle D.L., Moxley G., Dumenci L. Associations between statin use and changes in pain, function and structural progression: a longitudinal study of persons with knee osteoarthritis. Ann Rheum Dis 2013, 72:196-203.
72. Riddle D.L., Moxley G., Dumenci L. Response to comments in: statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study by Clockaerts etal. Ann Rheum Dis 2013, 72:e12.
73. Clockaerts S., Van Osch G.J., Bastiaansen-Jenniskens Y.M., Verhaar J.A., Van Glabbeek F., Van Meurs J.B., et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012, 71:642-647.
74. Conaghan P.G. The effects of statins on osteoarthritis structural progression: another glimpse of the Holy Grail?. Ann Rheum Dis 2012, 71:633-634.
75. Baker J.F., Walsh P., Mulhall K.J. Statins: a potential role in the management of osteoarthritis?. Joint Bone Spine 2011, 78:31-34.
76. Kadam U.T., Blagojevic M., Belcher J. Statin use and clinical osteoarthritis in the general population: a longitudinal study. JGen Intern Med 2013, 28:943-949.
77. Qvist P., Christiansen C., Karsdal M.A., Madsen S.H., Sondergaard B.C., Bay-Jensen A.C. Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 2010, 15:1-19.
78. Gaspoz J.M., Coxson P.G., Goldman P.A., Williams L.W., Kuntz K.M., Hunink M.G., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. NEngl J Med 2002, 346:1800-1806.
79. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009, 2:65-72. Heart Protection Study Collaborative Group.
80. Gage B.F., Cardinalli A.B., Albers G.W., Owens D.K. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995, 274:1839-1845.